Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1982644498
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
6
Hospital affiliations
925 Gessner Rd Ste 600,625
Houston, TX, 77024
Phone (713) 827-9525
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
255,899 services
Medicare patients, 2024
586
Average age 75
Drug cost, 2024
$11.5M
3,230 prescriptions
Company payments, 2025
$1,392
From 24 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Ronjay Rakkhit was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 85,680 times for 79 patients. In total Ronjay Rakkhit billed 255,899 services in 143 codes, and Medicare paid $3.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-03-18.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 85,680 | 79 | $0.27 | $24K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 19,300 | 18 | $44.36 | $856K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 7,950 | 11 | $0.11 | $881 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 6,900 | 51 | $0.10 | $712 |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 3,680 | 17 | $6.31 | $23K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,010 | 21 | $0.09 | $178 |
| 85025 Blood Count | Office | 1,462 | 483 | $7.57 | $11K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,390 | 25 | $0.71 | $991 |
| Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 996 | 20 | $109.49 | $109K |
| 99213 Office E&M - Established | Office | 917 | 455 | $64.38 | $59K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 834 | 372 | $10.91 | $9,102 |
| 80047 Clinical Chemistry | Office | 482 | 292 | $13.40 | $6,461 |
| J9045 Injection, carboplatin, 50 mg | Office | 392 | 11 | $2.85 | $1,116 |
| 96372 Injection Administration | Office | 354 | 58 | $10.75 | $3,805 |
| 96367 Intravenous Infusion, Hydration | Office | 323 | 29 | $21.75 | $7,025 |
By year: 2022 $2.2M for 266,612 services; 2023 $2.7M for 251,104 services; 2024 $3.2M for 255,899 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,462 | 483 | $7.57 | $11K |
| 80047 Clinical Chemistry | 482 | 292 | $13.40 | $6,461 |
| 36415 Venipuncture Blood Collection | 89 | 61 | $8.65 | $770 |
| 82565 Clinical Chemistry | 50 | 40 | $5.02 | $251 |
Medicare prescription drug claims, 2024
In 2024, the drug Ronjay Rakkhit prescribed most often to Medicare patients was Xarelto (Rivaroxaban), with 172 prescriptions and refills. In total Ronjay Rakkhit wrote 3,230 Medicare prescriptions that cost $11.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | 172 | 289 | 44 | $160K |
| Famciclovir Generic | 138 | 220 | 35 | $7,992 |
| Dexamethasone Generic | 137 | 148 | 54 | $2,430 |
| Exemestane Generic | 137 | 345 | 41 | $21K |
| Eliquis Apixaban | 130 | 205 | 31 | $119K |
| Ondansetron Odt Ondansetron | 102 | 104 | 74 | $1,936 |
| Revlimid Lenalidomide | 96 | 96 | 17 | $1.7M |
| Prednisone Generic | 91 | 122 | 25 | $520 |
| Granisetron Hcl Generic | 83 | 83 | 70 | $16K |
| Lidocaine-Prilocaine Lidocaine/Prilocaine | 83 | 83 | 66 | $794 |
| Anastrozole Generic | 76 | 175 | 18 | $886 |
| Hydroxyurea Generic | 71 | 177 | 21 | $1,733 |
| Aprepitant Generic | 64 | 64 | 15 | $23K |
| Gabapentin Generic | 62 | 72 | 15 | $627 |
| Abiraterone Acetate Generic | 60 | 68 | 11 | $98K |
Brand drugs: 1,066 claims; generic drugs: 2,164 claims; opioid claims: 94.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Ronjay Rakkhit $1,392 ($1,392 in general payments such as food, travel and fees) from 24 companies. The largest payer was Abbvie Inc. with $283.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 3 | $283 |
| GlaxoSmithKline, LLC. GSK | 5 | $123 |
| Tempus AI, Inc TEM | 6 | $123 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $117 |
| Janssen Biotech, Inc. JNJ | 5 | $110 |
| Pfizer Inc. PFE | 3 | $72.13 |
| Merck Sharp & Dohme LLC MRK | 3 | $66.29 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $59.69 |
| Array Biopharma Inc PFE | 2 | $54.24 |
| Agios Pharmaceuticals, Inc. AGIO | 2 | $43.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.